Scientists map how transitions from day to night control gene regulatory networks in cyanobacteria, revealing key orchestrators of metabolic switching.

Scientists uncover how cyanobacteria's circadian cycle controls carbon and energy metabolism, increasing carbon dioxide-to-bioproducts yields.

CACTUS provides AI-powered cheminformatics for autonomous science.

PNNL scientists use proteomics to unveil how high-density lipoproteins protect against cholesterol accumulation in the artery wall.

Computing and artificial intelligence aid scientists who seek to understand function-driven design and control of biological systems.

PNNL will engage with transmission planners and other regional partners through technical assistance and listening sessions with the goal of exploring opportunities to integrate equity into transmission planning.

Early life exposure to polycyclic aromatic hydrocarbons (PAHs), found in smoke, has been linked to developmental problems. To study the impacts of these pollutants, PAH metabolism in infants and adults were compared.

PMedIC, the PNNL and OHSU joint research collaboration, contributes to student success and impact in biomedicine.

Data reveals mechanisms in our bodies that can help us fight viral pathogenesis.

Pacific Northwest may face increase in summer heat-dome-like stationary waves.

The new PTM-Psi workflow opens the door for uncovering molecular insights within proteomics datasets.

Scientists developed a process (or pipeline) that combined molecular probes—a specific chemical that binds to microbes carrying out a particular function—with a method that isolated these cells from their complex community.

Scientists screen for nanobodies that recognize wild type and mutant functional proteins to develop a framework to disrupt protein interactions that can cause disease.

ExaGO, a power grid simulation and optimization platform developed at PNNL is the first of its kind to run on Frontier.

COVID-19 infections at PNNL early in the pandemic were caused by a wide variety of viral sequences, according to a new analysis by Laboratory researchers.

Gosline works to develop computational algorithms that are uniquely targeted for rare disease work by doing foundational research in model system development. This work can be expanded to all model systems in human disease.

Advanced proteomic analysis tools dig deep into human blood plasma to understand the molecular nature of advanced alcoholic disease.

Findings show method to better prepare human lung tissue for study; it represents the latest mass spectrometry-based omics advances.